Taiwan’s ASA Co. focuses on the research and development of personal stem cell products. In 2012, The patented biotechnology was transferred from Autologous Stem Cell Technology (ASCT) of Australia, an novel and advanced cell therapy product "Autologous Multi-lineage Potential Cells" (AMPC), the production process is closed system, with high safety and no infection. AMPC has been used in clinical adjuvant therapy for more than 2,000 autologous intravenous infusions abroad, including kidney disease, cardiovascular disease, hepatobiliary and gastrointestinal diseases, leukemia, hormonal imbalance, male and female infertility, osteoarthritis, joint degeneration, metabolic syndrome , nervous disorders, immune disorders, sexual dysfunction, medical aesthetics (hair follicle hyperplasia and replacement of hyaluronic acid and other fillers) and other clinical diseases, all cases have no adverse reactions, shown clinical safety, and significant medical effects.